Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
about
Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersIncreased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors.Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.High sensitivity of megakaryocytic progenitor cells contained in placental/umbilical cord blood to the stresses during cryopreservation.Unrelated donor bone marrow transplantation in adults: some current controversies.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialHaemopoietic stem cell transplantation from unrelated donors.The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation.Immunotherapy of AML: future directionsInterleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia.Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord bloodPartially matched transplants with allogeneic CD34+ blood cells.Pathogenesis and management of graft-versus-host disease.Mixed allogeneic chimerism and tolerance to composite tissue allografts.Umbilical cord blood for allogeneic transplantation in children and adults.A modified vascularized whole knee joint allotransplantation model in the rat.Opportunistic infections after blood and marrow transplantation.Human leukocyte antigen gene polymorphism and the histocompatibility laboratoryUnrelated donor hematopoietic transplantation.Chronic graft-versus-host disease: clinical manifestation and therapy.IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.Medullary allotransplant in acute myeloblastic leukemia in a child.Living bone allotransplants survive by surgical angiogenesis alone: development of a novel method of composite tissue allotransplantation.Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy.The role of donor age in naive T-cell recovery following allogeneic hematopoietic stem cell transplantation: the younger the better.Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host diseaseCord blood-derived hematopoietic stem/progenitor cells: current challenges in engraftment, infection, and ex vivo expansion.Clinical and experimental uses of umbilical cord blood.Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.Tissue typing in support of unrelated hematopoietic cell transplantation.Biological significance of HLA locus matching in unrelated donor bone marrow transplantation.HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita.Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host diseaseExpansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.
P2860
Q26767501-E0DDE74B-7068-40EC-ACCC-D4B9C1EDB498Q33179317-68626ED4-9C5D-4F94-87D7-3CD13B140740Q33335306-A6FEBF32-C65A-4DA9-9C84-9FC12109BFE0Q33361807-2FC69358-6337-42AA-840D-D86FD231433DQ33536887-E6596211-F6A3-42C9-88C1-CF575BDD2036Q33653406-8A12728A-D920-4194-AE0E-0DAAD6C9F8BDQ33656177-B8C290F6-9EBB-47C0-8872-EE6137BE49F9Q33661926-170C7751-7702-4D09-B4D7-EC4993571E53Q33893052-2E15A08A-FD11-488C-9D11-A6855E1D1F38Q34038570-17F53490-5D3A-46AF-91E0-13C1A8EBB67CQ34048540-15747D67-30D3-401C-BFC2-45C9BB7BC417Q34066649-E210C132-0BDF-4889-955D-128C60C52681Q34077479-BC328202-02D7-4709-9E2D-F4CCB68228A5Q34126623-4D0ADA4E-A329-4555-98C7-4D6DA0683DCFQ34178470-81274F60-F969-4082-9B3A-32254EDB7501Q34208957-39EF7930-7D2C-4008-83E2-FCE8EC3C93AEQ34294774-5EEC3030-0171-4D41-941D-3961E3ABED37Q34326276-5CB7F5EB-242A-45FC-9C1D-8D78FDA1B0CAQ34326698-47E8922C-EAD3-474D-90E4-8DF37161158EQ34339695-812ADA8B-6AF3-49AE-A7BA-F0B404DD6F6DQ34491107-30472FCA-AFEC-47B3-A62B-50C55832F2C6Q34520207-4CF43726-9CF2-4B24-9129-0A1274EAEBFAQ34527672-314DBE58-40CD-4BF9-A39A-7EE0FAAA1708Q34561047-B5A233AE-C4BB-4AD7-95E9-955B5CC38FC9Q34616704-8BC55CC2-D603-486B-A104-AE215D873319Q34667853-4D8C5D15-2F98-4137-8FA0-6B9681F79B9AQ34680950-A47B6A96-269C-43F6-9C63-56B972515C8BQ34769856-CC80FA02-B67D-418A-8CDA-4BE3A66AF28CQ34791351-29B82F1D-8525-4C5D-96B6-379F974E69D0Q34986499-A163C6CD-BD0D-49B8-B25D-4E96332F35A5Q35038926-ACA58D4C-0E0C-4762-A3E6-E6E1D24DBC32Q35061893-19261E98-C110-43B2-A998-C78CD70CA811Q35073502-83E2D757-F86B-4D55-8C2A-03BB2985CE19Q35080070-5FC1B723-2A9E-4A65-885A-4DE13401E253Q35080101-9694BB9A-0EA8-40D3-9A8A-C420F22B81D8Q35128241-5B1FFF1F-2B5E-4FFA-A582-A87ACC165358Q35128245-1A46B201-B17C-4F99-A838-F9ECD1A6A41FQ35202316-7A5899C6-BE16-41A7-BDC9-6A2655CF3EB4Q35485880-5BDDBF9C-9872-42A2-8B39-8DE6F9D320A2Q35575711-0C72285C-AB87-429D-B5C6-E8E3893C63E1
P2860
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մարտին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@ast
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@en
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@nl
type
label
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@ast
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@en
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@nl
prefLabel
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@ast
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@en
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@nl
P2093
P1476
Analysis of 462 transplantatio ...... National Marrow Donor Program.
@en
P2093
Champlin R
Filipovich A
Gajewski J
Henslee-Downey J
McCullough J
P304
P356
10.1056/NEJM199303043280901
P407
P577
1993-03-01T00:00:00Z